Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Tips For Tradespeople Working in the Cold Weather

Work doesn’t stop when the weather gets cold. But at this time of year, it's more important than ever to understand how to keep yourself safe and what steps to take when working in cold winter conditions. From your clothing to your vehicle, your well-being to your insurance, there's a lot to think about when the temperature drops. Whether your trade involves working inside or outside, there are considerations to bear in mind for winter working.   [A snow covered town with houses and a river Description automatically generated]   Below, the experts at MyJobQuote.co.uk 

Expert Shares the Top Energy Saving Tips for 2025

Energy costs are consistently on the rise, and most of us are looking desperately for ways to cut back our bills in the new year.     Here are some top tips from energy expert William Hobbs at MyJobQuote.co.uk  on how to make 2025 your year for saving energy!   Adjust Your Thermostat   Adjusting your thermostat to maintain a consistent and comfortable temperature within your home is a vital first step to saving on energy costs. However, contrary to popular belief, this doesn’t necessarily mean setting it higher in the summer and

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has accepted BioArctic’s partner Eisai’s Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). Leqembi is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a

Nordea Bank Abp: Repurchase of own shares on 13.01.2025

Nordea Bank AbpStock exchange release – Changes in company’s own shares13.01.2025 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 13.01.2025 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |139,747|10.91 |1,524,863.

Financial effects as a result of the transfer of a majority stake in the subsidiary Rediem Capital AB

On 19 December 2024, TF Bank AB (publ) ("TF Bank" or the "Bank") announced that the closing date for the transfer of the majority stake in the subsidiary Rediem Capital AB ("Rediem") to Alektum Holding AB (publ) and Erik Selin Fastigheter Aktiebolag had been expedited. Furthermore, it was announced that the Bank would provide further information on the financial effects of the transfer on the Bank's financial records, which is included in this press release. The closing of the shares in Rediem took place on December 20, 2024, with the preliminary purchase price amounting to SEK 472

Repurchase of shares in Synsam during January 7, 2025 – January 10, 2025 (week 2)

Synsam AB (publ) (LEI code: 5493000TMEGW9DHNOQ70) ("Synsam" or the "Company") has during January 7, 2025, to January 10, 2025, repurchased in total 180,000 own shares (ISIN code: SE0016829709) as part of the share buy-back program initiated by the board of directors of Synsam in order to adjust the Company's capital structure.The repurchases form part of the share buy-back program of maximum MSEK 160 announced by Synsam on November 19, 2024, and which runs during the period from November 22, 2024, until the date of the 2025 annual general meeting. The share buy-back program is being carried

SciBase announces outcome of directed issue and preliminary outcome of rights issue

SciBase Holding AB (”SciBase” or the ”Company”) today announces the preliminary outcome of the capital raise, consisting of a rights issue of units of approximately SEK 59.3 million (the “Rights Issue”) and a directed issue of units, deviating from existing shareholders' preferential rights, of approximately SEK 22.5 million (the ”Directed Issue”), that was announced on  November 12, 2024 (the ”Capital Raise”). All 16,669,624 units in the Directed Issue have been subscribed and paid for, and thus the Board of Directors of SciBase plans to resolve on allocation of units to the investors in the

Mandatum plc: Disclosure Under Chapter 9 Section 5 of the Securities Market Act (Altor Fund Manager AB)

Mandatum Plc, Stock exchange release, 13 January 2025 at 20:00 EET Mandatum plc (Business ID 3355142-3) has received a notification, pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act, that the breakdown of Altor Fund Manager AB’s (registration number 556962-9149, Sweden) and its funds’ direct or indirect holding of the shares and votes in Mandatum plc has changed.Altor Invest 8 AS has on 13 January 2025 converted 100,000 financial instruments under the swap into shares by way of physical settlement. The total number of (i) the shares and voting rights held directly

Issue of Equity

13 January 2025   Ashoka WhiteOak Emerging Markets Trust plc   Issue of Equity   Ashoka WhiteOak Emerging Markets Trust plc (the ‘Company’) announces that it has issued 150,000 new ordinary shares of one penny each (the ‘Ordinary Shares’) pursuant to its block listing facility. The Ordinary Shares will be issued at a price of 121.3 pence per Ordinary Share, a premium to the prevailing net asset value per Ordinary Share.   Following the issue of Ordinary Shares, the Company's issued share capital will comprise 33,119,329 Ordinary Shares and this is the total number of

Record date determined for dividend in 24SevenOffice Group

The Extraordinary General Meeting (the "EGM") on 9 January 2025 in 24SevenOffice Group AB (publ) resolved on a dividend to the shareholders of SEK 6.85 per share, corresponding to a total amount of SEK 465,544,988.20, payable in cash. The EGM authorized the Board of Directors to resolve on the record date for the dividend.    The Board of Directors has resolved that the record date for the dividend shall be on 17 January 2025. The dividend is expected to be paid through the agency of Euroclear Sweden AB on 22 January 2025.

disposing remaining Castellum shares to its parent

Akelius Residential Property AB has agreed to sell its remaining 51,800,760 shares in Castellum. The buyer is Akelius Apartments Limited,and the agreed price is SEK 130 per share.   Akelius Residential Property AB does not hold any shares in Castellum after the sale.   Akelius Residential will remain the owner of the shares in Castellum until such time as relevant government authority approvals have been granted, i.e. approval from the Inspectorate of Strategic Products (ISP).Such approval is expected during the first calendar quarter of 2025.  CEO, Ralf Spann · The

Tele2 announces changes to the Group Leadership Team

Stockholm – Tele2 AB (“Tele2”) (Nasdaq Stockholm: TEL2 A and TEL2 B) announces that Kim Hagberg, Executive Vice President, Chief Operations, will leave her position effective from today.Kim joined Tele2 in 2013 and has held many positions over the years and has been part of the Group Leadership Team since 2018. -          I thank Kim for her unwavering dedication and leadership during her time with us. Her contributions have been instrumental in driving operational excellence and positioning Tele2 for continued success, says Jean Marc Harion, CEO & President at Tele2.   For more

Roc Oil Company Pty Limited announces the final outcome of the recommended cash offer to the shareholders of Tethys Oil AB

THIS ANNOUNCEMENT IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED BY APPLICABLE LAW. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT

Arctic Bioscience – Primary insiders participating in convertible loan facility

Reference is made to the stock exchange release from earlier today, 13[th] January 2025, regarding new funding, including a convertible loan facility of NOK 15 million.The following primary insiders, or closely related companies to primary insiders, are a part of the total investor consortium: · Ronja Capital Investment AS, a company closely related to Board Member Tore Tønseth, NOK 3,0 million · Vartdal Holding AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,0 million · Brødrene Vartdal AS, a company closely related to Board Member Jan Endre Vartdal, NOK 1,

FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025

Fiskars Corporation   Stock Exchange Release 13.01.2025 at 18:30 EET/EEST   FISKARS CORPORATION: ACQUISITION OF OWN SHARES 13.01.2025   Date 13.01.2025  Exchange transaction Buy  Share class FSKRS  Amount  2000  Average price/share 14.5861 EURHighest price/share 14.6200 EURLowest price/share 14.5000 EURTotal price 29,172.20 EUR      The share buybacks are executed in compliance with Regulation No. 596/2014 of the European

OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

STOCKHOLM, SWEDEN – January 13, 2025 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces that the Company has entered into a non-binding agreement with the intention to partner with pharmaceutical leader Molteni Farmaceutici (“Molteni”) regarding exclusive rights to commercialization of BupiZenge™ in Europe.The Company has signed a non-binding offer from Molteni for a commercial partnership to introduce BupiZenge™ in Europe with the goal to sign the definitive licensing agreement no later than April 30th, 2025. During a period of exclusivity, the parties will complete planning,

SlotsRank Highlights the Top Global Markets for Online Slots in 2025

Stockholm, Sweden – January 2025 – SlotsRank , a renowned platform offering insights into the online gaming industry, highlights the dynamic growth of online slots across the globe in 2025. SlotsRank, a dedicated segment of CasinoRank specializing in slot games, provides additional expertise on trends shaping this ever-evolving market, emphasizing how technological advancements and diverse themes continue to drive the global appeal and innovation that captivate players and sustain engagement.Emerging Trends in Online Slots The online slots industry continues to

Arctic Bioscience – funded to cash positive

· Arctic Bioscience is now funded through a NOK 30 million loan facility. · Strong 30% y/y growth in sales revenues in 2024 and prospects of continued strong growth in coming years. · Psoriasis drug candidate HRO350 on track for 12 months readout end of Q1.Reference is made to the stock exchange notice 29[th] October 2024 on Q3 2024 Operational update. The Company announced working on various financing opportunities, where a liquidity contribution of around NOK 30 million was estimated to bring the Company into a positive cash flow position. New funding of NOK 30 million is now

#25-9 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Invitation to presentation of Addtech's Interim Report on February 4 at 10.00 a.m. (CET)

Welcome to a conference call regarding Addtech's Interim Report for the third quarter that will be published on February 4 at around 08.15 a.m. (CET). The conference starts at 10.00 a.m. (CET) and is aimed at analysts, the media and investors and will be held in English. The presentation will be hosted by CEO Niklas Stenberg and CFO Malin Enarson. The presentation material will be available in advance here: https://www.addtech.com/investors-and-media/presentations If you wish to participate via webcast please use the link below. Via the webcast you are able to ask written questions. The

Heimdal and Watsoft Team Up to Strengthen MSP Cybersecurity in France

COPENHAGEN, Denmark, and PARIS, France, January 13, 2025 — Heimdal, a top European cybersecurity company, is teaming up with Watsoft, a French IT distributor focused on Managed Service Providers (MSPs).This partnership will help MSPs in France deal with today’s growing cybersecurity challenges by simplifying how they manage security and offering reliable tools from a trusted European provider. Making Cybersecurity Easier for MSPs MSPs face a lot of pressure from rising cyber threats and rules about protecting data locally. With this partnership, Heimdal and Watsoft will provide

There are no items matching the current filter
There are no more items matching the current filter
Back to top